(NASDAQ: PAHC) Phibro Animal Health's forecast annual revenue growth rate of 10.86% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.43%.
Phibro Animal Health's revenue in 2025 is $1,106,080,000.On average, 3 Wall Street analysts forecast PAHC's revenue for 2025 to be $51,690,339,997, with the lowest PAHC revenue forecast at $51,047,304,717, and the highest PAHC revenue forecast at $52,312,434,912. On average, 3 Wall Street analysts forecast PAHC's revenue for 2026 to be $55,733,126,622, with the lowest PAHC revenue forecast at $52,705,400,917, and the highest PAHC revenue forecast at $59,953,845,598.
In 2027, PAHC is forecast to generate $57,751,097,380 in revenue, with the lowest revenue forecast at $54,483,347,294 and the highest revenue forecast at $61,569,129,485.